Sutro Biopharma, Inc.
Price Action
Technical Summary
EMERGING TRENDSutro Biopharma, Inc. shows underlying uptrend characteristics but has temporarily lost support at the 50-day moving average. Relative strength is leading (RS Rating: 99), indicating clear outperformance against the broad market. Earnings growth of 68% provides fundamental context to the price action. Investors should exercise caution due to high volatility (90% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $28.19 | +8.26% | ABOVE |
| 50 SMA | $32.08 | -4.87% | BELOW |
| 100 SMA | $26.84 | +13.72% | ABOVE |
| 150 SMA | $21.62 | +41.15% | ABOVE |
| 200 SMA | $18.55 | +64.56% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is STRO in an uptrend right now?
STRO has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is STRO overbought or oversold?
STRO's RSI (14) is 50. The stock is in neutral territory, neither overbought nor oversold.
Is STRO outperforming the market?
STRO has a Relative Strength (RS) Rating of 99 out of 99. Yes, STRO is a market leader, outperforming 99% of all stocks over the past 12 months.
Where is STRO in its 52-week range?
STRO is trading at $30.52, which is 70% of its 52-week high ($43.85) and 69% above its 52-week low ($0.67).
How volatile is STRO?
STRO has a Beta of 1.03 and 52-week volatility of 90%. It's more volatile than the S&P 500 - expect bigger swings.